BJH - volume 7, issue Abstract Book BHS, january 2016
L. Knoops MD, PhD, G. Verhoef MD, PhD, Z. Berneman MD, PhD, D. Selleslag MD, N. Straetmans MD, PhD, L. Noens MD, PhD, P. Lewalle MD, PhD, M. André MD, PhD, D. Pranger MD, P. Zachée MD, PhD, E. Strobbe , L.J. McGarry , T. Devos MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
D. Selleslag MD, C. Lambert MD, PhD, P. Zachée MD, PhD, D. Dierickx MD, PhD
BJH - volume 5, issue 3, september 2014
E. Mourin MD, A. Van Hoof MD, PhD, A. Bosly MD, PhD, C. Bonnet MD, V. De Wilde MD, PhD, C. Doyen MD, C. Hermans MD, PhD, A. Janssens MD, PhD, L. Michaux MD, PhD, W. Schroyens MD, PhD, A. Sonet MD, E. Van den Neste MD, PhD, G. Verhoef MD, PhD, P. Zachée MD, PhD, M. André MD, PhD
Mantle cell lymphoma was recognised in the nineties and is characterised by the t(11;14)(q13;q32) translocation which results in overexpression of cyclin D1.1 This disease represents approximately 6% of all non-Hodgkin’s lymphomas. Mantle cell lymphoma generally affects patients over 60 years-old. Most patients have advanced disease (>70 % Ann Arbor stage IV). Several efforts have been made to predict outcome in mantle cell lymphoma. The cell-proliferation marker Ki-67, the Mantle Cell Lymphoma International Prognostic Index, fluorodeoxyglucose positron emission tomography and minimal residual disease are prognostic tools. For young patients, chemoimmunotherapy followed by high-dose chemotherapy plus stem cell transplantation is the treatment of choice. For the main group of older patients, chemo-immunotherapy followed by maintenance with rituximab is the gold standard. In relapses, temsirolimus is actually registered and new drugs, such as ibrutinib, are currently evaluated with promising preliminary results.2–5
(BELG J HEMATOL 2014;5(3):89–96)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
prof. F. Baron , P. Zachée MD, PhD, J. Maertens MD, PhD, T. Kerre MD, PhD, A. Ory , L. Seidel , C. Graux MD, PhD, P. Lewalle MD, PhD, H. Schouten , K. Theunissen MD, R. Schots MD, PhD, Y. Beguin MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
K. Beel MD, PhD, A. De Vooght MD, P. Zachée MD, PhD, P. De schouwer MD, M. Kockx MD
BJH - volume 4, issue 3, september 2013
F. Van Obbergh MD, A. Van Hoof MD, PhD, G. Verhoef MD, PhD, D. Dierickx MD, PhD, V. De Wilde MD, PhD, F. Offner MD, PhD, D. Bron MD, PhD, A. Sonet MD, M. André MD, PhD, A. Janssens MD, PhD, C. Bonnet MD, B. Deprijck MD, P. Zachée MD, PhD, A. Kentos MD, PhD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD
The sub-committee on lymphoproliferative disorders of the Belgian Hematological Society has met several times to prepare guidelines on the management of patients with peripheral T-cell lymphomas. Each panellist’s expert provided interpretation of the evidence, based on literature review and personal experience. The available evidence was systematically discussed prior to formulating recommendations. A systematic approach to obtain consensus of expert opinion was used. After each meeting, the draft guideline was circulated to all experts for comment and approval. The present guidelines focus on general management of peripheral T-cell lymphomas with special emphasis on more specific disease-adapted strategies.
(BELG J HEMATOL 2013;4(3):90–101)
Read moreBJH - volume 4, issue 2, june 2013
E. Philipse MD, T. Martens MD, A. Bufi MD, M. Kockx MD, P. Zachée MD, PhD, K. Wu MD, PhD
A 16-year-old Moroccan woman was referred to our centre because of bilateral cervical lymphadenopathy, high fever and weight loss. A malignant lymphoma was suspected in the lymph node biopsy. Histopathologic review of the lymph node biopsy showed extensive necrosis and nuclear debris with no viable remaining cells. A new lymph node biopsy was performed and the diagnosis of histiocytic necrotising lymphadenitis (Kikuchi-Fujimoto disease) was made. This is a rare, benign and self-limiting disease that mainly affects young women.
BELG J HEMATOL 2013;4(2):66–69)
Read more
Top
